Search results
Results From The WOW.Com Content Network
The Centers for Medicare & Medicaid Services (CMS) is a federal agency within the United States Department of Health and Human Services (HHS) that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program (CHIP), and health insurance portability standards.
The Center for Medicare and Medicaid Innovation (CMMI; also known as the CMS Innovation Center) is an organization of the United States government under the Centers for Medicare and Medicaid Services (CMS). [1] It was created by the Patient Protection and Affordable Care Act, the 2010 U.S. health care reform legislation.
Medicare Prescription Drug, Improvement, and Modernization Act; Long title: An act to amend title XVIII of the Social Security Act to provide for a voluntary prescription drug benefit under the medicare program and to strengthen and improve the medicare program, and for other purposes.
There are four savings programs available for Medicare recipients. Each one covers a different set of costs related to Medicare expenses. Qualified Medicare Beneficiary (QMB): This program helps ...
HealthCare.gov is a health insurance exchange website operated by the United States federal government under the provisions of the Affordable Care Act (ACA), informally referred to as "Obamacare", which currently serves the residents of the U.S. states which have opted not to create their own state exchanges.
Out of more than 30,000 deficiencies CMS identified at facilities across the country from 2007 to 2017, less than 3% were classified as immediate jeopardy.
The Blue Button Logo, April 2012. The Blue Button is a system for patients to view online and download their own personal health records.Several Federal agencies, including the Departments of Defense, Health and Human Services, and Veterans Affairs, implemented this capability for their beneficiaries. [1]
The Janssen doctors and statisticians now had more complete results from the long-term study of children and adolescents using Risperdal. They confirmed that the claim on the current label that gynecomastia was “rare” (meaning that it occurred in fewer than one-tenth of 1 percent of patients) was understated by a factor of more than 50.